BI Asset Management Fondsmaeglerselskab A S Buys 6,692 Shares of Medpace Holdings, Inc. $MEDP

BI Asset Management Fondsmaeglerselskab A S lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 76.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,444 shares of the company’s stock after acquiring an additional 6,692 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned approximately 0.05% of Medpace worth $7,941,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of the company. Quent Capital LLC bought a new stake in Medpace during the 3rd quarter valued at $25,000. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Employees Retirement System of Texas bought a new position in Medpace in the 2nd quarter valued at approximately $36,000. Root Financial Partners LLC purchased a new stake in shares of Medpace during the third quarter valued at $38,000. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in shares of Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after acquiring an additional 27 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insiders Place Their Bets

In related news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the transaction, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 320,192 shares of company stock worth $192,909,762 over the last ninety days. Corporate insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Barclays boosted their price objective on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. TD Cowen reissued a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Robert W. Baird set a $613.00 price objective on Medpace in a report on Friday, October 24th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, BMO Capital Markets initiated coverage on Medpace in a research report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $491.27.

Medpace Stock Performance

Shares of MEDP opened at $541.27 on Friday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The stock has a market capitalization of $15.25 billion, a PE ratio of 37.85, a P/E/G ratio of 1.89 and a beta of 1.42. The company’s 50-day simple moving average is $580.60 and its 200-day simple moving average is $536.29.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.